SCHEMBL24484554

SCHEMBL24484554

N#Cc1ccc(C(=O)C2(F)CCN(C(=O)c3cccnc3-c3ccncn3)CC2)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP46A1 Q9Y6A2 6/20 0.52
▸ GPR6 P46095 3/20 0.41
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2C8 P10632 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ PKM P14618 2/20 0.37
▸ USP30 Q70CQ3 1/20 0.37
▸ HCRTR1 O43613 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ GRM5 P41594 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24484643 0.85 CYP46A1 (0.55) CYP46A1GPR6CYP3A4CYP2C8CYP2C9
SCHEMBL24484717 0.84 CYP46A1 (0.50) CYP46A1GPR6CYP3A4CYP2C8CYP2C9
SCHEMBL24484654 0.84 CYP46A1 (0.50) CYP46A1GPR6CYP3A4CYP2C8CYP2C9
SCHEMBL24484659 0.84 CYP46A1 (0.50) CYP46A1GPR6CYP3A4CYP2C8CYP2C9
SCHEMBL24484711 0.84 CYP46A1 (0.57) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484710 0.80 CYP46A1 (0.64) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL30600323 0.80 CYP46A1 (0.56) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484611 0.80 CYP46A1 (0.56) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484655 0.79 CYP46A1 (0.57) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL22719482 0.78 CYP46A1 (0.58) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312522-A1 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF SAGE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230312522-A1 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF SAGE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
WO-2022261510-A1 NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE SAGE THERAPEUTICS, INC. (US) 2022-12-15 — — WO disclosed
WO-2022115620-A1 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS SAGE THERAPEUTICS, INC. (US) 2022-06-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312522-A1 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF CYP46A1, CYP26A1, CYP4A22 CYP46A1 1/4885GPR6 1922/4885CYP3A4 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback